clinical trial · NCT05844449
Evaluation of Long-Term Safety and Efficacy of Vanzacaftor/Tezacaftor/Deutivacaftor in Cystic Fibrosis Participants 1 Year of Age and Older
Vertex Pharmaceuticals Incorporated·phase3·enrolling by invitation·n = 174
Cystic FibrosisVNZ/TEZ/D-IVA
brief summary
The purpose of this study is to evaluate the long-term safety, tolerability, and efficacy of vanzacaftor/tezacaftor/deutivacaftor (VNZ/TEZ/D-IVA) in participants with cystic fibrosis (CF).
started
Aug 11, 2023
primary completion
Jul 30, 2029
completion
Jul 30, 2029
last updated
Feb 5, 2026
official title
A Phase 3, Open-label Study Evaluating the Long-term Safety and Efficacy of Vanzacaftor/Tezacaftor/Deutivacaftor Triple Combination Therapy in Cystic Fibrosis Subjects 1 Year of Age and Older
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol